undamentalytics Newsletter
Sign in

Pyxis Oncology, Inc. revenue

Pyxis Oncology, Inc.'s revenue was $13.9m in fiscal 2025, down 14.2% on the year before.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2024Dec 20242025Dec 2025
Revenue1614
Growth on the year before—−14.2%
Gross profit1611
Gross margin97.1%82.8%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Sale of Royalty Rights $11M 79.7% ▲ 38.0%
Milestone Revenue $2.8M 20.3% —
Royalty $0 0.0% ▼ 100.0%

From Pyxis Oncology, Inc.'s 10-K filed March 23, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Pyxis Oncology, Inc. $16.1m — —
Keros Therapeutics, Inc. $14.9m -93.6% —
Proqr Therapeutics N.V. $18.0m -12.1% —
Cytomx Therapeutics, Inc. $18.3m -87.0% -38.7%
Celularity Inc $18.7m -58.1% 7.2%
Alector, Inc. $13.9m -82.9% -48.6%

Compare with peers

Head to head: KROS vs PYXSPRQR vs PYXSCTMX vs PYXS

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Pyxis Oncology, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Pyxis Oncology, Inc.